CN1178914C - 4-苄基-1-[2-(4-羟基-苯氧基)乙基]-哌啶-3,4-二醇 - Google Patents

4-苄基-1-[2-(4-羟基-苯氧基)乙基]-哌啶-3,4-二醇 Download PDF

Info

Publication number
CN1178914C
CN1178914C CNB018085911A CN01808591A CN1178914C CN 1178914 C CN1178914 C CN 1178914C CN B018085911 A CNB018085911 A CN B018085911A CN 01808591 A CN01808591 A CN 01808591A CN 1178914 C CN1178914 C CN 1178914C
Authority
CN
China
Prior art keywords
benzyl
piperidine
ethyl
phenoxy
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018085911A
Other languages
English (en)
Chinese (zh)
Other versions
CN1443166A (zh
Inventor
A
A·阿兰尼
ض�
B·布特尔曼
����ڵ¹���
M-P·海茨内德哈特
G·贾什克
���ɶ��ؼ�����
E·皮纳尔
R·维勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1443166A publication Critical patent/CN1443166A/zh
Application granted granted Critical
Publication of CN1178914C publication Critical patent/CN1178914C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50—Aroyl radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB018085911A 2000-04-25 2001-04-17 4-苄基-1-[2-(4-羟基-苯氧基)乙基]-哌啶-3,4-二醇 Expired - Fee Related CN1178914C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108769 2000-04-25
EP00108769.1 2000-04-25

Publications (2)

Publication Number Publication Date
CN1443166A CN1443166A (zh) 2003-09-17
CN1178914C true CN1178914C (zh) 2004-12-08

Family

ID=8168543

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018085911A Expired - Fee Related CN1178914C (zh) 2000-04-25 2001-04-17 4-苄基-1-[2-(4-羟基-苯氧基)乙基]-哌啶-3,4-二醇

Country Status (18)

Country Link
US (1) US6432985B2 (enExample)
EP (1) EP1278730B1 (enExample)
JP (1) JP3831255B2 (enExample)
KR (1) KR100527527B1 (enExample)
CN (1) CN1178914C (enExample)
AR (1) AR028357A1 (enExample)
AT (1) ATE313527T1 (enExample)
AU (1) AU785153B2 (enExample)
BR (1) BR0110233A (enExample)
CA (1) CA2407345C (enExample)
DE (1) DE60116080T2 (enExample)
DK (1) DK1278730T3 (enExample)
ES (1) ES2254422T3 (enExample)
MX (1) MXPA02010573A (enExample)
PE (1) PE20011229A1 (enExample)
UY (1) UY26681A1 (enExample)
WO (1) WO2001081309A2 (enExample)
ZA (1) ZA200208134B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103403003A (zh) * 2011-03-02 2013-11-20 霍夫曼-拉罗奇有限公司 桥连哌啶衍生物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
EP1585430B1 (en) 2002-11-14 2017-01-11 Brainsgate Ltd. Surgical tools and techniques for stimulation
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
NZ582124A (en) * 2007-05-21 2012-07-27 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
AU2009228660B2 (en) * 2008-03-27 2012-11-29 Evotec International Gmbh Methods for treating disorders using NMDA NR2B-subtype selective antagonist
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
ES2463766T3 (es) * 2008-08-12 2014-05-29 Zinfandel Pharmaceuticals, Inc. Método de identificación de factores de riesgo de la enfermedad de Alzheimer
WO2012096873A1 (en) 2011-01-10 2012-07-19 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
US11319314B2 (en) 2016-11-08 2022-05-03 Hoffmann-La Roche Inc. Phenoxytriazoles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103403003A (zh) * 2011-03-02 2013-11-20 霍夫曼-拉罗奇有限公司 桥连哌啶衍生物
CN103403003B (zh) * 2011-03-02 2016-09-14 霍夫曼-拉罗奇有限公司 桥连哌啶衍生物

Also Published As

Publication number Publication date
DE60116080D1 (de) 2006-01-26
ATE313527T1 (de) 2006-01-15
BR0110233A (pt) 2003-01-21
US20010047014A1 (en) 2001-11-29
AU785153B2 (en) 2006-10-05
PE20011229A1 (es) 2001-12-08
KR100527527B1 (ko) 2005-11-09
CA2407345A1 (en) 2001-11-01
JP3831255B2 (ja) 2006-10-11
ZA200208134B (en) 2004-01-22
AU6021301A (en) 2001-11-07
AR028357A1 (es) 2003-05-07
CN1443166A (zh) 2003-09-17
DK1278730T3 (da) 2006-05-01
KR20040007216A (ko) 2004-01-24
EP1278730A2 (en) 2003-01-29
MXPA02010573A (es) 2003-03-10
WO2001081309A2 (en) 2001-11-01
US6432985B2 (en) 2002-08-13
ES2254422T3 (es) 2006-06-16
WO2001081309A3 (en) 2002-01-17
EP1278730B1 (en) 2005-12-21
CA2407345C (en) 2009-04-07
JP2004509837A (ja) 2004-04-02
DE60116080T2 (de) 2006-08-24
UY26681A1 (es) 2001-10-25

Similar Documents

Publication Publication Date Title
CN1178914C (zh) 4-苄基-1-[2-(4-羟基-苯氧基)乙基]-哌啶-3,4-二醇
US6124323A (en) 4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists
CN1155574C (zh) 醚毒蕈碱性拮抗剂
KR101432112B1 (ko) 도파민 ｄ3 수용체 리간드로서의 신규 카보닐화된 (아자)사이클로헥산
JP5237324B2 (ja) セロトニン様作用薬としてのインダゾールアミド化合物
US6790854B2 (en) Diphenylalkylamine derivatives useful as opioid receptor agonists
US20050153963A1 (en) N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy
CN1910150A (zh) 作为gcs抑制剂的哌啶衍生物
KR20040103973A (ko) Ｎ-[페닐(피페리딘-2-일)메틸]벤즈아미드의 유도체, 그의제조 방법 및 치료법에서의 그의 용도
CN1326441A (zh) 4－芳酰基－哌啶－ccr－3受体拮抗剂ⅲ
CN1314905A (zh) 毒蕈碱性拮抗剂
CN1142141C (zh) 乙磺酰基哌啶衍生物
KR20060002747A (ko) 치환 알킬 아미도 피페리딘
US6916822B2 (en) Phenoxyalkylamine derivatives useful as opioid δ receptor agonists
US20040186103A1 (en) Substituted alkyl amido piperidines
JP5052497B2 (ja) ヒスタミンｈ３受容体アンタゴニストとしてのピロリジン誘導体
JP2005532399A (ja) Ｍｃｈ１アンタゴニストとしての二級アミノアニリンピペリジン類およびその使用
CN1188111A (zh) 4－羟基－哌啶衍生物
JP4713474B2 (ja) Ｎｋ３受容体アンタゴニストとしてのシクロプロピル誘導体
CN101137646A (zh) Ccr5受体拮抗剂的合成
HK1034076A (en) 1,4-diazacycloheptane derivatives
JPWO2001070689A1 (ja) オピオイドδ受容体作用薬として有用なジフェニルアルキルアミン誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20041208

Termination date: 20110417